Physician profile
Corazon A Veza
NPI 1447242110
$1,579.43
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $180.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $289.40 | 2019-2020 | |
| Amgen INC. | $268.07 | 2019 | |
| Lilly USA, LLC | $132.04 | 2019-2020 | |
| Janssen Biotech, INC. | $91.01 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $86.64 | 2019 | |
| Merck Sharp & Dohme LLC | $75.25 | 2019-2020 | |
| Eisai INC. | $56.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $53.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.89 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.93 | 2019 | |
| Pfizer INC. | $39.21 | 2019 | |
| Genzyme Corporation | $37.19 | 2019 | |
| Foundation Medicine, INC. | $37.05 | 2019 | |
| Celgene Corporation | $33.01 | 2019-2020 | |
| Incyte Corporation | $31.63 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $31.59 | 2019 | |
| Puma Biotechnology, INC. | $30.26 | 2019-2020 | |
| Seagen INC. | $28.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.44 | 2020 | |
| Taiho Oncology, INC. | $21.32 | 2019 | |
| Genentech USA, INC. | $17.99 | 2019 | |
| Tesaro, INC. | $15.45 | 2019 | |
| Daiichi Sankyo INC. | $15.11 | 2019 | |
| Karyopharm Therapeutics INC. | $13.38 | 2020 | |
| Gilead Sciences, INC. | $13.00 | 2019 | |
| Eusa Pharma (US) LLC | $12.94 | 2019 | |
| Clovis Oncology, INC. | $12.20 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corazon Veza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.